Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Discover the Company Revolutionizing Casino Gaming (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EXEL)

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

Business Wire September 12, 2023

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Business Wire August 31, 2023

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Business Wire August 24, 2023

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Business Wire August 23, 2023

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Business Wire August 21, 2023

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Business Wire August 1, 2023

Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.

Business Wire July 23, 2023

Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

Business Wire July 18, 2023

Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis' Board

Business Wire May 31, 2023
View More News ››

Opinion & Analysis (NDAQ:EXEL)

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Streetwise Reports April 21, 2020

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

Stock picks including a coal play

J.W. Cotton November 4, 2009
View More Opinion ››

Bullboard Posts (NDAQ:EXEL)

fighting cancers

with a profitable operation valued at about $7 billion and a diverse portfolio of treatments. These include its Cabometyx drug for...
jw1trader - August 24, 2022

FYI (Seeking Alpha) Bret Jensen

I offer up three predictions that are highly probable in my opinion for Gilead in 2017 and its shareholders. 1. The dividend is hiked...
Carlos66 - January 11, 2017

RE:Anyone watching this?

I'm in let see what happen soon?? Mark
mark26 - August 16, 2014

Anyone watching this?

this is going to JUMP! $11 dollar target set by Piper Jaffray... get in this quick!!! http://www.fool.com/investing/general/2014/04/04...
stopstockingme - April 6, 2014

Venture Exchange News

http://www.tsx.com/en/news_events/news_releases/10-5-2007_TSXVenture-NewListingELE.html EXCELSIOR ENERGY LIMITED ("ELE"...
Oldmannorth - October 9, 2007

RE: Excelsior News - Sept 25

Bye Bye CNQ, hello TSX Venture. New symbol is ELE starts trading Tuesday October 9th.
britexile - October 9, 2007
View more Bullboard ››

Osino Resources Corp.

Osino Resources Corp.

Osino Resources Corp is a Canadian company, focused on the exploration and development of gold projects in Namibia. The ...
View More »